tyrosine has been researched along with Parkinson Disease, Secondary in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agim, ZS; Cannon, JR | 1 |
| Feng, JH; Hu, XL; Lin, J; Lv, XY; Wang, H; Ye, WC; Zhang, XQ | 1 |
| Harada, N; Kakiuchi, T; Kanazawa, M; Muramatsu, S; Ohba, H; Tsukada, H | 1 |
| Bahri, MA; Becker, G; Garraux, G; Hustadt, F; Lemaire, C; Luxen, A; Michel, A; Plenevaux, A | 1 |
| Bankiewicz, KS; Eberling, JL; Emborg, ME; Nagy, D; Oiwa, Y; Pivirotto, P | 1 |
| Akaike, A; Hayashi, K; Inden, M; Kitamura, Y; Kondo, J; Nishimura, K; Shimohama, S; Sugimoto, H; Takata, K; Taniguchi, T; Tsuchiya, D; Yanagida, T; Yanagisawa, D | 1 |
| Carey, RJ; Dai, H; Huston, JP; Pinheiro-Carrera, M; Schwarting, RK; Tomaz, C | 1 |
| Hayase, N; Horikoshi, S; Ohye, C; Shibasaki, T; Tomiyoshi, K; Watanabe, K | 1 |
| Bankiewicz, KS; Eberling, JL; Jagust, WJ; Jordan, S; VanBrocklin, HF | 1 |
| Bankiewicz, KS; Bringas, J; Eberling, JL; Jagust, WJ; Pivirotto, P; Taylor, S; VanBrocklin, HF | 1 |
| Andersen, JK; Andreassen, OA; Beal, MF; Bogdanov, M; Dedeoglu, A; Ferrante, RJ; Jiang, D; Klivenyi, P; Lancelot, E; Mueller, G | 1 |
| Bankiewicz, KS; Bringas, J; Budinger, TF; Cunningham, J; Eberling, JL; Harvey-White, J; Jagust, W; Kohutnicka, M; Pivirotto, P | 1 |
| Boveris, AD; Cadenas, E; Poderoso, JJ; Riobó, NA; Schöpfer, FJ | 1 |
| Halbhübner, K; Herken, H; Kehr, W; Loos, D | 1 |
| Poirier, LJ | 1 |
| Fujitake, J; Kuno, S; Mizuta, E | 1 |
| McGeer, PL | 1 |
| Baker, AB; Martin, WE; Resch, JA | 1 |
18 other study(ies) available for tyrosine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Alterations in the nigrostriatal dopamine system after acute systemic PhIP exposure.
Topics: Animals; Corpus Striatum; Dopamine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Imidazoles; Male; Neurotoxicity Syndromes; Oxidative Stress; Parkinson Disease, Secondary; Rats, Sprague-Dawley; Substantia Nigra; Time Factors; Tyrosine | 2018 |
Synthesis and biological evaluation of clovamide analogues as potent anti-neuroinflammatory agents in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Cell Line; Disease Models, Animal; Humans; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Neuroprotective Agents; Nitric Oxide Synthase Type II; Parkinson Disease, Secondary; Tyrosine | 2018 |
Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Topics: Animals; Brain; Carbidopa; Dihydroxyphenylalanine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Enzyme Inhibitors; Levodopa; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Presynaptic; Tyrosine | 2016 |
Comparative assessment of 6-[
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Fluorine Radioisotopes; Image Processing, Computer-Assisted; Male; Neostriatum; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Receptors, Presynaptic; Stereotyped Behavior; Tyrosine | 2017 |
Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Carotid Arteries; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Fluorine Radioisotopes; Histocytochemistry; Humans; Injections, Intra-Arterial; Macaca mulatta; Male; Neurochemistry; Parkinson Disease, Secondary; Parkinsonian Disorders; Tomography, Emission-Computed; Tyrosine; Tyrosine 3-Monooxygenase | 2003 |
Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
Topics: Adrenergic Agents; Aldehydes; alpha-Synuclein; Animals; Behavior, Animal; Blotting, Western; CD11b Antigen; Cell Count; Cell Line; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Functional Laterality; Glial Fibrillary Acidic Protein; Humans; Immunohistochemistry; Male; Neurodegenerative Diseases; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Parkinsonian Disorders; Rats; Rats, Wistar; Reactive Oxygen Species; Rotarod Performance Test; Rotation; Substantia Nigra; Synaptophysin; Time Factors; Tyrosine; Tyrosine 3-Monooxygenase | 2005 |
L-DOPA metabolism in cortical and striatal tissues in an animal model of parkinsonism.
Topics: Animals; Dopamine; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Stereotaxic Techniques; Tyrosine | 1995 |
Positron emission tomography with 4-[18F]fluoro-L-m-tyrosine in MPTP-induced hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Central Nervous System Stimulants; Corpus Striatum; Fluorine Radioisotopes; Macaca; Parkinson Disease, Secondary; Reference Values; Tomography, Emission-Computed; Tyrosine | 1995 |
PET studies of functional compensation in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Progression; Dopamine Agents; Fluorine Radioisotopes; Macaca mulatta; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Neurotoxins; Pargyline; Parkinson Disease, Secondary; Tomography, Emission-Computed; Tyrosine | 1997 |
A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Macaca mulatta; Parkinson Disease, Secondary; Tomography, Emission-Computed; Tyrosine | 1998 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catechols; Convulsants; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Female; Free Radicals; Glutathione; Glutathione Peroxidase; Heterozygote; Homovanillic Acid; Homozygote; Huntington Disease; Male; Malonates; Mice; Mice, Inbred Strains; Mice, Knockout; MPTP Poisoning; Nitro Compounds; Oxidative Stress; Parkinson Disease, Secondary; Propionates; Tyrosine | 2000 |
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Carbidopa; Catheterization; Caudate Nucleus; Cell Line; Dependovirus; Dopamine; Drug Administration Routes; Drug Combinations; Fluorine Radioisotopes; Genetic Therapy; Genetic Vectors; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Neurons; Parkinson Disease, Secondary; Prodrugs; Putamen; Tomography, Emission-Computed; Tyrosine; Tyrosine 3-Monooxygenase | 2000 |
The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cattle; Nerve Tissue Proteins; Nitric Oxide; Oxidation-Reduction; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Peroxynitrous Acid; Serum Albumin, Bovine; Superoxide Dismutase; Synucleins; Tyrosine | 2002 |
Action of dopamine agonists on parkinson-like muscle rigidity induced by 6-aminonicotinamide.
Topics: 6-Aminonicotinamide; Animals; Brain Chemistry; Corpus Striatum; Diencephalon; Dihydroxyphenylalanine; Electromyography; Levodopa; Limbic System; Lisuride; Male; Muscles; Niacinamide; Parkinson Disease, Secondary; Rats; Tyrosine | 1979 |
Dopaminergic agonists in animal models of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Cats; Disease Models, Animal; Haplorhini; Levodopa; Parkinson Disease, Secondary; Piribedil; Rats; Reserpine; Tyrosine | 1975 |
Interference of 3-O-methyldopa with L-dopa treatment for MPTP-induced parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Injections, Intravenous; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Receptors, Dopamine; Tyrosine | 1990 |
Tyrosine hydroxylase and parkinsonism.
Topics: Animals; Brain; Carbon Monoxide; Catecholamines; Dopamine; Haplorhini; Humans; Manganese; Mixed Function Oxygenases; Parkinson Disease; Parkinson Disease, Secondary; Serotonin; Substantia Nigra; Tyrosine | 1971 |
Juvenile parkinsonism.
Topics: Adult; Age Factors; Aged; Diagnosis, Differential; Dihydroxyphenylalanine; Dopamine; Humans; Male; Metabolism, Inborn Errors; Mixed Function Oxygenases; Parkinson Disease; Parkinson Disease, Secondary; Pedigree; Spasm; Tranquilizing Agents; Tremor; Tyrosine; Tyrosine 3-Monooxygenase | 1971 |